← All trials
NCT04428684
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 29, 2018
- Primary completion
- Apr 1, 2020
- Completion date
- Jun 7, 2020
- First posted
- Jun 12, 2020
- Last posted
- Jun 12, 2020
- Enrollment
- 80
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Peptigroupe IncLead sponsor
- Peptigroupe IncStudy director
- Pharmaxi LLCStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.